注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白致肝损伤1例报告

潘高峰; 傅茂英; 郜玉峰

doi:10.3969/j.issn.1001-5256.2019.06.036

注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白致肝损伤1例报告

DOI: 10.3969/j.issn.1001-5256.2019.06.036

1. 昆山市第一人民医院感染科
2. 安徽医科大学第一附属医院感染科

基金项目:

安徽省自然科学基金(1608085MH164)；昆山市社会发展科技专项(KS1719)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1815
- HTML全文浏览量: 15
- PDF下载量: 278
- 被引次数: 0
出版历程
- 出版日期: 2019-06-20

Liver injury induced by recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein for injection

Department of Infectious Diseases, The First People's Hospital, Kunshan

Research funding:

摘要

摘要:
<正>注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白是我国研发的单克隆抗体药物。它竞争性地与TNFα结合,阻碍TNFα与细胞表面TNFα受体结合,从而降低了TNFα的生物学活性[1-2]。该药物主要被用于强直性脊柱炎的治疗,其常见的不良反应为注射部位的肿胀、疼痛、瘙痒、红斑等,但也可导致感染、腹痛、咳嗽、眩晕及肝酶升高等少见不良反应[3]。近期本科收治1例该药物所致肝损伤患者,具体报告如下。1病例资料患者男性,22岁,因"发现肝功能异常2个月余,纳差1周"于2018年8月14日入昆山市第一人民院。既往史:强直性脊柱
- 脊柱炎,强直性 /
- 受体,肿瘤坏死因子,Ⅱ型 /
- 重组融合蛋白质类 /
- 药物性肝损伤 /
- 病例报告
- spondylitis, ankylosing /
- receptors, tumor necrosis factor, type Ⅱ /
- recombinant fusion proteins /
- drug-induced liver injury /
- case reports

HTML全文

参考文献(10)

[1]SAKAI R, TANAKA M, NANK T, et al.Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients rcceiving anticytokine therapy with different target molecules[J].Ann Rheum Dis, 2012, 71 (11) :1820-1826.

[2]LIU J, ZHU CH.Statistical analysis for adverse reactions induced by etanercept[J].Clin Med Eng, 2012, 19 (12) :2258-2259. (in Chinese) 刘娟, 朱灿辉.益赛普致不良反应统计分析[J].临床医学工程, 2012, 19 (12) :2258-2259.

[3]ZHANG Q, HUANG SJ, LUO T, et al.A case of mild liver injury induced by recombinant human tumor necrosis factor receptor-antibody fusion protein for injection[J].Pharm Care Res, 2017, 17 (6) :460-469. (in Chinese) 张琴, 黄姗剑, 骆婷, 等.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白致轻度肝损伤一例[J].药学服务与研究, 2017, 17 (6) :460-469.

[4]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[5]YU YC, FAN Y, CHEN CW.Diagnosis and treatment of druginduced liver injury[J].J Clin Hepatol, 2018, 31 (6) :1160-1165. (in Chinese) 于乐成, 范晔, 陈成伟.药物性肝损伤的诊断和治疗[J].临床肝胆病杂志, 2018, 31 (6) :1160-1165.

[6]KARCZMAREK-BOROWSKA B, SALEK-ZAN'A.Hepatotoxicity of molecular targeted therapy[J].Contemp Oncol (Pozn) , 2015, 19 (2) :87-92.

[7]FONTANA RJ.Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J].Gastroenterology, 2014, 146 (4) :914-928.

[8]FISHER K, VUPPALANCHI R, SAXENA R.Drug-induced liver injury[J].Arch Pathol Lab Med, 2015, 139 (7) :876-887.

[9]KLEINER DE, CHALASANI NP, LEE WM, et al.Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J].Hepatology, 2014, 59 (2) :661-670.

[10]YU YC, MAO YM, CHEN CW, et al.CSH guideline for the diagnosis and treatment of drug-induced liver injury[J].Hepatol Int, 2017, 11 (3) :221-241.

施引文献

资源附件(0)

访问统计